Sugi Predict

Sugi Predict / Compounds / SCHEMBL394329

SCHEMBL394329

SCHEMBL394329

Nc1ccc(F)c([N+](=O)[O-])c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.64
▸ TDP1 Q9NUW8 5/20 0.64
▸ CYP3A4 P08684 2/20 0.64
▸ ALOX15 P16050 2/20 0.64
▸ HIF1A Q16665 1/20 0.62
▸ TSHR P16473 2/20 0.60
▸ RECQL P46063 1/20 0.60
▸ MAPK1 P28482 1/20 0.60
▸ HSD17B10 Q99714 1/20 0.60
▸ L3MBTL1 Q9Y468 1/20 0.60
▸ VCAM1 P19320 1/20 0.58
▸ ATM Q13315 1/20 0.48
▸ PDE7A Q13946 4/20 0.46
▸ MAPT P10636 4/20 0.45
▸ LMNA P02545 2/20 0.45
▸ HTT P42858 2/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ MITF O75030 1/20 0.45
▸ GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL350687 0.83 TDP1 (0.64) ALDH1A1TDP1CYP3A4ALOX15HIF1A
SCHEMBL31147788 0.82 ALDH1A1 (0.50) ALDH1A1TDP1CYP3A4ALOX15HIF1A
SCHEMBL28812018 0.81 ALDH1A1 (0.56) ALDH1A1TDP1CYP3A4ALOX15HIF1A
SCHEMBL4408381 0.81 TDP1 (0.51) ALDH1A1TDP1CYP3A4ALOX15HIF1A
SCHEMBL1254184 0.80 TDP1 (0.72) ALDH1A1TDP1CYP3A4ALOX15TSHR
SCHEMBL402945 0.79 ALDH1A1 (0.62) ALDH1A1TDP1CYP3A4ALOX15HIF1A
SCHEMBL78083 0.78 ALDH1A1 (1.00) ALDH1A1TDP1CYP3A4ALOX15TSHR
SCHEMBL29358067 0.78 ALDH1A1 (1.00) ALDH1A1TDP1CYP3A4ALOX15TSHR
SCHEMBL153657 0.78 ALDH1A1 (0.69) ALDH1A1TDP1CYP3A4ALOX15TSHR
SCHEMBL11579276 0.78 ALDH1A1 (0.67) ALDH1A1TDP1HIF1ATSHRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119752419-A Organic-inorganic hybrid perovskite phase-change material, and preparation method and application thereof 天津大学 2025-04-04 — — CN claimed
CN-115466848-B Method for extracting multiple elements from vanadium-rich slag and application 西安建筑科技大学 2024-02-20 — — CN claimed
CN-116354901-A Thiazolidinedione compound and preparation method and application thereof 郑州大学 2023-06-30 — — CN claimed
CN-114805223-B 2, 4-disubstituted quinazoline compound for inhibiting EGFR, preparation method and application 自贡市第四人民医院(自贡市急救中心) 2023-05-09 — — CN claimed
CN-115466848-A Method for extracting multiple elements from vanadium-rich slag and application 西安建筑科技大学 2022-12-13 — — CN claimed
CN-114805223-A 2, 4-disubstituted quinazoline compound for inhibiting EGFR (epidermal growth factor receptor), and preparation method and application thereof 自贡市第四人民医院(自贡市急救中心) 2022-07-29 — — CN claimed
CN-112827368-A Anti-pollution reverse osmosis membrane and preparation method thereof 中化(宁波)润沃膜科技有限公司 2021-05-25 — — CN claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 — — EP claimed
CN-105622426-A Preparation method of 4-fluoro-N-methyl-3-nitroaniline ZHEJIANG DINGLONG TECH CO LTD 2016-06-01 — — CN claimed
CN-104151178-A 2-amino-4-(beta-hydroxyethylamino) methoxybenzene and preparation method of 2-amino-4-(beta-hydroxyethylamino) methoxybenzene sulfate ZHEJIANG DRAGON CHEMICAL CO LTD 2014-11-19 — — CN claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 — — WO claimed
US-20050124631-A1 Inhibitors of polyq-aggregation MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2005-06-09 — — US claimed
EP-1416931-A1 INHIBITORS OF POLYQ-AGGREGATION Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2004-05-12 — — EP claimed
WO-2003015772-A1 INHIBITORS OF POLYQ-AGGREGATION MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2003-02-27 — — WO claimed
US-5891199-A CONDENSATION PRODUCT OF A CHITOSAN WITH A HALOGEN-SUBSTITUTED NITROANILINE COMPOUND. HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (KGAA) (DE) 1999-04-06 — — US claimed
US-5414128-A Dehydrofluorination for amination CASSELLA AG (DE) 1995-05-09 — — US claimed
EP-0646108-A1 HYDROXYPROPYLATED 2-NITRO-P-PHENYLENEDIAMINES, PREPARATION METHOD THEREFOR AND USE THEREOF FOR DYEING KERATIN FIBRES L'OREAL (FR) 1995-04-05 — — EP claimed
WO-1994000414-A1 HYDROXYPROPYLATED 2-NITRO-P-PHENYLENEDIAMINES, PREPARATION METHOD THEREFOR AND USE THEREOF FOR DYEING KERATIN FIBRES L'OREAL (FR) 1994-01-06 — — WO claimed
EP-0226973-B1 4-BIS(2'-HYDROXYETHYL)AMINO-1-(3'-HYDROXYPROPYL)AMINO-2-NITRO-BENZENE, PROCESS FOR ITS PREPARATION AND MEANS FOR DYEING HAIR Wella Aktiengesellschaft (DE) 1991-03-06 — — EP claimed
US-3959377-A FROM 4-FLUORO-3-NITROANILINE AND ANILINE CLAIROL INCORPORATED (US) 1976-05-25 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124631-A1 Inhibitors of polyq-aggregation HTT, ATXN2, ATXN2L ALDH1A1 3178/4885TDP1 24/4885CYP3A4 4340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.